Literature DB >> 20339006

Diastolic function is strongly and independently associated with cardiorespiratory fitness in central obesity.

M Turzyniecka1, S H Wild, A J Krentz, A J Chipperfield, G F Clough, C D Byrne.   

Abstract

Cardiorespiratory fitness [maximal O2 consumption (VO2max)] is an independent risk factor for type 2 diabetes; but in individuals at risk, factors influencing VO2max are poorly understood. We tested the hypothesis that VO2max is associated with diastolic function [subendocardial variability ratio (SEVR), %], as diastolic function influences myocardial perfusion. We studied 47 men and women with central obesity without diabetes. We measured fitness (VO2max) by treadmill testing and diastolic function (SEVR%) by pulse-wave analysis. We measured other factors influencing this relationship: insulin sensitivity [whole body glucose uptake-to-insulin concentration ratio (M/I)] by hyperinsulinemic euglycemic clamp, fatness by MR imaging and dual-energy X-ray absorptiometry, physical activity energy expenditure (metabolic equivalents of tasks) by the Sensewear Pro2 device, and muscle microvascular exchange capacity (capillary filtration coefficient) by venous plethysmography. Mean age of the subjects was 51+/-9 (SD) yr. VO2max was associated with SEVR% (r=0.50, P=0.001), fatness (r=-0.39, P=0.008), and HbA1c (r=-0.35, P=0.018), but not with whole body glucose uptake-to-insulin concentration ratio, metabolic equivalents of tasks, or capillary filtration coefficient. In regression modeling with age, sex, fatness, and SEVR% as explanatory variables, only age, sex, and SEVR% were independently associated with VO2max (SEVR%--standardized B coefficient=0.37, 95% confidence interval=0.003-0.18, P=0.007). This model identified 46% of the variance in VO2max (R2=0.46, P=0.0001). There was a strong, independent association between VO2max and a measure of diastolic function in sedentary individuals with central obesity.

Entities:  

Mesh:

Year:  2010        PMID: 20339006     DOI: 10.1152/japplphysiol.00023.2010

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  5 in total

1.  Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy.

Authors:  Marco Canepa; Lars L Sorensen; Iraklis Pozios; Veronica L Dimaano; Hong-Chang Luo; Aurelio C Pinheiro; James B Strait; Claudio Brunelli; M Roselle Abraham; Luigi Ferrucci; Theodore P Abraham
Journal:  Am J Cardiol       Date:  2013-10-15       Impact factor: 2.778

2.  The relationship between pulse waveform analysis indices, endothelial function and clinical outcomes in patients with peripheral artery disease treated using percutaneous transluminal angioplasty during a one-year follow-up period.

Authors:  Paweł Kaczmarczyk; Paweł Maga; Rafał Niżankowski; Rafał Januszek; Marzena Frołow; Mikołaj Maga; Jolanta Kościelniak; Andrzej Belowski
Journal:  Cardiol J       Date:  2018-04-03       Impact factor: 2.737

3.  Effects Of Exercise Training With Dietary Restriction On Arterial Stiffness, Central Hemodynamic Parameters And Cardiac Autonomic Function In Obese Adolescents.

Authors:  Junhao Huang; Qinhao Lai; Dan Wang; Honggang Yin; Jingwen Liao; Shen Wang; Fengpeng Xu; Xiaohui Hou; Min Hu
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-17       Impact factor: 3.168

4.  The role of inflammation, the autonomic nervous system and classical cardiovascular disease risk factors on subendocardial viability ratio in patients with RA: a cross-sectional and longitudinal study.

Authors:  Aamer Sandoo; Athanassios D Protogerou; James Hodson; Jacqueline P Smith; Evi Zampeli; Petros P Sfikakis; George D Kitas
Journal:  Arthritis Res Ther       Date:  2012-11-28       Impact factor: 5.156

Review 5.  Metabolic equivalents of task are confounded by adiposity, which disturbs objective measurement of physical activity.

Authors:  Tuomo T Tompuri
Journal:  Front Physiol       Date:  2015-08-11       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.